Q-omics provides the consensus-scored KRTAP1-1 profile across patient tissues and cancer cell-line models. KRTAP1-1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRTAP1-1 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, KRTAP1-1 RNA expression shows 6,688 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where KRTAP1-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP1-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP1-1 survival associations across molecular data types. KRTAP1-1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP1-1 RNA expression–survival associations across cancer types. High KRTAP1-1 expression shows unfavorable associations in KIRC, UVM, CESC, ACC and SKCM, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRTAP1-1 RNA expression.
This table summarizes KRTAP1-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP1-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP1-1 shows lower tumor expression in BRCA, KIRC, HNSC and KICH and higher tumor expression in KIRP and UCEC. The BRCA box plot shows higher KRTAP1-1 RNA expression in normal versus tumor tissue (log2 FC = −0.165, t-test p < 0.001).
This table shows molecular features associated with KRTAP1-1 in patient tissues and cancer cell lines. In patient samples, KRTAP1-1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP1-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
